Carisma Therapeutics (CARM) Expected to Post Earnings on Monday

Carisma Therapeutics (NASDAQ:CARM) is expected to be announcing its resultson Monday, August 17th. Analysts expect Carisma Therapeutics to post earnings of ($0.1139) per share and revenue of $4.2290 million for the quarter.

Carisma Therapeutics Stock Down 12.0%

CARM stock opened at $0.00 on Friday. Carisma Therapeutics has a 12 month low of $0.00 and a 12 month high of $0.56. The firm has a market cap of $92,059.00, a P/E ratio of 0.00 and a beta of -9.09. The company’s 50-day moving average price is $0.01 and its two-hundred day moving average price is $0.02.

Institutional Trading of Carisma Therapeutics

An institutional investor recently bought a new stake in Carisma Therapeutics stock. Jane Street Group LLC acquired a new stake in Carisma Therapeutics Inc. (NASDAQ:CARM) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 150,810 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned about 0.36% of Carisma Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 44.27% of the company’s stock.

About Carisma Therapeutics

Carisma Therapeutics, Inc is a clinical-stage biotechnology company headquartered in the United States that focuses on harnessing the innate immune system to treat cancer and inflammatory diseases. Through its proprietary CARMA (Chimeric Antigen Receptor Macrophage) platform, Carisma engineers macrophages and other myeloid cells to seek out, engulf and destroy diseased cells while reprogramming the surrounding microenvironment. This approach aims to address key limitations of existing T-cell therapies by leveraging the unique trafficking and immunomodulatory properties of innate immune cells.

The company’s lead oncology candidate, CT-0508, employs a HER2-targeted CAR expressed on macrophages to infiltrate and remodel HER2-positive solid tumors.